Andrew Dudum Sells 188,888 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $20.75, for a total value of $3,919,426.00. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $695,166.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Andrew Dudum also recently made the following trade(s):

• On Thursday, June 20th, Andrew Dudum sold 45,755 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.97, for a total value of $1,050,992.35.
• On Tuesday, June 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.88, for a total value of $3,755,093.44.
• On Wednesday, May 1st, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.54, for a total value of $2,368,655.52.

Hims & Hers Health Trading Down 2.3 %

HIMS stock opened at $20.21 on Thursday. The stock has a 50-day moving average price of $18.92 and a two-hundred day moving average price of $14.20. The stock has a market cap of $4.34 billion, a PE ratio of -2,020.50 and a beta of 1.08. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.05) EPS. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. FNY Investment Advisers LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $48,000. Belpointe Asset Management LLC acquired a new stake in Hims & Hers Health in the 3rd quarter valued at about $76,000. Certuity LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $109,000. Custom Index Systems LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $132,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $155,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of analyst reports. Canaccord Genuity Group increased their price target on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, May 22nd. Jefferies Financial Group increased their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Piper Sandler increased their price target on Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, May 7th. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.